Alpha -Tocopherol Succinate D- Ascorbic Acid Chole

證據等級: L5

預測適應症: 0 個

Multivitamin Combination (B1/B2/B3/B6/B9/B12 + C + D3 + E): No Repurposing Prediction Available

One-Sentence Summary

This product is a nine-component vitamin combination — Thiamine Mononitrate (B1), Riboflavin 5’-Phosphate (B2), Niacinamide (B3), Pyridoxine HCl (B6), Folic Acid (B9), Methylcobalamin (B12), Ascorbic Acid (C), Cholecalciferol (D3), and D-alpha-Tocopherol Succinate (E) — classically used as nutritional supplementation. The TxGNN model returned no predicted indications for this combination, as the multi-ingredient formulation could not be resolved to a single DrugBank entity required for prediction. There is currently insufficient computational and regulatory data to support a repurposing evaluation.

Quick Overview

Item	Content
Original Indication	Nutritional supplementation (B-complex + vitamins C, D3, E)
Predicted New Indication	None — TxGNN returned no candidates
TxGNN Prediction Score	Not available
Evidence Level	L5 — no predictions generated
US Market Status	Not marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

This combination contains nine distinct active ingredients across two vitamin classes: water-soluble vitamins (B1, B2, B3, B6, B9, B12, C) and fat-soluble vitamins (D3, E). Each component carries a distinct mechanism — for example, B-vitamins serve as enzyme cofactors in energy metabolism and one-carbon cycling, Vitamin D3 regulates calcium homeostasis and immune modulation, and Vitamin E acts as a lipid-soluble antioxidant. As a combined formulation, however, the product does not map to any single DrugBank identifier.

The TxGNN model operates on individual drug entities identified by DrugBank IDs. Because this formulation is a multi-ingredient combination with no unified DrugBank mapping, the model was unable to generate repurposing predictions. This is a known limitation of graph-based drug repurposing models when applied to fixed-dose combinations — the knowledge graph cannot represent the combined pharmacology as a single node.

Individual components of this combination have established evidence for repurposing investigation in separate contexts (e.g., Vitamin D in autoimmune disease, Methylcobalamin in neuropathy). However, evaluating them as a single combined entity computationally is not feasible without decomposition into constituent ingredients and re-running the pipeline per component.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN pipeline produced no output for this combination because the multi-ingredient formulation cannot be resolved to a single DrugBank node; repurposing analysis for the combination as a unified entity is therefore not currently possible.

To proceed, the following is needed:

Decompose the combination: Run TxGNN individually on each of the nine active ingredients using their respective DrugBank IDs (e.g., DB00162 for Vitamin D3, DB00126 for Ascorbic Acid, DB01402 for Methylcobalamin, etc.)
Identify the primary indication: Clarify whether this formulation targets a specific population or condition (e.g., pregnancy supplementation, post-surgical recovery, oncology supportive care), which would scope any repurposing analysis
Regulatory data retrieval: Obtain package insert from the originating country to establish the approved indication and any safety warnings
DrugBank mapping: Confirm DrugBank IDs for all nine ingredients to enable evidence collection via PubMed and ClinicalTrials.gov per component
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.